腫瘤學人工智慧市場：按組件、癌症類型、治療類型、最終用戶和地區分類

Artificial Intelligence in Oncology Market, By Component, By Cancer Type, By Treatment Type, By End User, By Region

出版日期: 2026年03月27日 | 出版商:

Coherent Market Insights | 英文 153 Pages | 商品交期: 2-3個工作天內

價格

簡介目錄

預計到 2026 年，腫瘤領域的人工智慧 (AI) 市場規模將達到 28.723 億美元，到 2033 年將達到 221.662 億美元。預計從 2026 年到 2033 年，該市場將以 33.9% 的複合年成長率成長。

報告範圍		報告詳情
基準年：	2025	2026年市場規模：	28.723億美元
歷史數據時期：	2020-2024	預測期：	2026-2033
2026年至2033年預測期間的複合年成長率：	33.90%	2033 年預計值：	221.662億美元

人工智慧（AI）在腫瘤學領域發揮著至關重要的作用。目前已有多種AI產品用於輔助癌症篩檢、診斷、治療和藥物研發。其中，由AI驅動的癌症篩檢工具是領先的產品之一。這些工具利用基於龐大醫學影像資料庫訓練的深度學習演算法，幫助醫師偵測CT掃描、MRI和乳房X光檢查等影像檢查中的異常情況。它們能夠快速分析大量影像，並突出顯示僅憑肉眼篩檢可能遺漏的可疑區域。這提高了早期腫瘤檢測的準確性，並挽救了更多生命。然而，演算法需要不斷更新新數據才能持續改進。此外，由於AI可能無法有效區分罕見癌症類型，因此也存在誤診的風險。

人工智慧的其他重要應用包括癌症診斷、預後預測和治療。透過將機器學習應用於大量的基因組和臨床癌症資料集，人工智慧能夠識別複雜的模式，獲得新的見解，並比人類更準確地預測治療結果。這有助於為每位患者量身定做個人化和標靶治療。人工智慧還能透過輔助標靶辨識、化合物篩檢和臨床試驗最佳化，加速藥物研發進程。

市場動態

癌症發生率的上升以及癌症治療決策日益複雜化，是推動腫瘤學領域採用人工智慧解決方案的主要動力。數位健康數據的可用性和運算能力的提升正在加速先進人工智慧技術的發展。然而，開發精準的臨床級人工智慧解決方案所需的大量投資和成本仍然是一個主要限制因素。此外，人工智慧決策過程缺乏可解釋性和可理解性，也阻礙了其廣泛應用。另一方面，人工智慧透過實現個人化治療方案來幫助克服抗藥性，這蘊藏著巨大的機會。科技公司與研究機構之間的合作旨在進一步證明人工智慧的臨床應用價值。

從區域來看，北美市場佔據主導地位，這主要得益於其高昂的醫療成本和良好的醫療服務可近性。然而，亞太地區預計將成為成長最快的市場，這主要受中國和印度等國家的推動。這一成長歸功於經濟成長、可支配收入的增加、醫療基礎設施的不斷完善以及先進癌症診斷工具的日益普及。

本次調查的主要特點

本研究確定了各個細分市場的潛在商機，並說明了該市場具有吸引力的投資提案矩陣。
此外，本研究還深入分析了市場促進因素、限制因素、機會、新產品發布和核准、市場趨勢、區域展望以及主要參與者採取的競爭策略。
本研究根據以下參數對全球腫瘤人工智慧市場的主要參與者進行了分析：公司亮點、產品系列、主要功能、財務表現和策略。
透過利用本報告中的見解，企業行銷負責人和經營團隊將能夠就未來的產品發布、產品升級、市場擴張和行銷策略做出明智的決策。
全球腫瘤人工智慧市場報告的目標受群眾外包括投資者、供應商、產品製造商、經銷商、新參與企業和金融分析師等產業相關人員。
透過各種用於分析全球腫瘤人工智慧市場的策略矩陣，相關人員將能夠更輕鬆地做出決策。

北美洲
- 美國
- 加拿大
歐洲
- 英國
- 德國
- 法國
- 義大利
- 西班牙
- 俄羅斯
- 其他歐洲國家
亞太地區
- 中國
- 印度
- 日本
- 澳洲
- 韓國
- ASEAN
- 其他亞太國家
拉丁美洲
- 巴西
- 墨西哥
- 阿根廷
- 其他拉丁美洲國家
中東
- GCC
- 以色列
- 其他中東國家
非洲
- 北非
- 中非
- 南非

第8章公司概況：腫瘤學人工智慧市場

NVIDIA Corporation
Digital Diagnostics Inc.
ConcertAI
Median Technologies
PathAI
Azra AI
IBM
Siemens Healthcare GmbH
Intel Corporation
GE HealthCare
Microsoft
Zebra Medical Vision
Babylon

第9章參考文獻與調查方法

參考
調查方法

簡介目錄

Product Code: CMI6509

Artificial Intelligence in Oncology Market is estimated to be valued at USD 2,872.3 Mn in 2026 and is expected to reach USD 22,166.2 Mn by 2033, growing at a compound annual growth rate (CAGR) of 33.9% from 2026 to 2033.

Report Coverage		Report Details
Base Year:	2025	Market Size in 2026:	USD 2,872.3 Mn
Historical Data for:	2020 To 2024	Forecast Period:	2026 To 2033
Forecast Period 2026 to 2033 CAGR:	33.90%	2033 Value Projection:	USD 22,166.2 Mn

Artificial intelligence (AI) plays an important role in oncology. There are various types of AI products that are helping in cancer screening, diagnosis, treatment, and drug development. One of the major products is an AI-assisted cancer screening tool. These tools use deep learning algorithms that have been trained on huge databases of medical images. They help physicians detect abnormalities in scans like CT, MRI, or mammograms. They can rapidly analyze a large number of images and highlight suspect areas that the doctor may miss with human screening alone. This improves the accuracy of detecting tumors at early stages and increases the number of lives saved. However, the algorithms need continuous updates with new data to improve over time. Misdiagnosis is also a risk because the AI may not be able to distinguish rare cancer types effectively.

Other important applications include the use of AI in cancer diagnostics, prognosis, and therapeutics. Using machine learning on vast pools of genomic and clinical cancer datasets, AI can recognize complex patterns, emerge with new insights, and predict treatment responses better than humans. This helps with customized and targeted therapy. AI is also speeding up drug development by assisting in target identification, compound screening, and clinical trial optimization.

Market Dynamics

Rising cancer incidence coupled with the increasing complexity of cancer treatment decisions is a key factor driving the adoption of AI solutions in oncology. The growing availability of digital health data and computational power is facilitating the development of advanced AI technologies. However, the high investment and costs required for the development of precision and clinical-grade AI solutions are a major restraint. Lack of interpretability and understanding of how AI arrives at its decisions also limits widespread adoption. Meanwhile, the potential of AI to help overcome drug resistance by enabling personalized treatment selection presents an opportunity. Partnerships between technology companies and research institutes aim to further validate the clinical applicability of AI.

Among regions, North America dominates the market due to high healthcare expenditures and better access to care. However, Asia Pacific is poised to be the fastest-growing market arena, led by countries like China and India. This growth can be attributed to growing economies, rising disposable incomes, expanding medical infrastructure, and the increasing adoption of technologically advanced cancer diagnostic tools.

Key features of the study

It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market.
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players.
It profiles key players in the global artificial intelligence in oncology market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies.
Key companies covered as a part of this study include Azra AI, IBM Corporation, Siemens Healthineers AG, Intel Corporation, GE HealthCare, NVIDIA Corporation, Digital Diagnostics Inc., ConcertAI, Median Technologies, PathAI, Microsoft, Zebra Medical Vision, and Babylon.
Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics.
The global artificial intelligence in oncology market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global artificial intelligence in oncology market.

Market Segmentation

By Component (Revenue, USD Mn, 2021 - 2033)
Software/Platform
Hardware
Services
By Cancer Type (Revenue, USD Mn, 2021 - 2033)
Breast Cancer
Lung Cancer
Prostate Cancer
Colorectal Cancer
Brain Tumor
Others
By Treatment Type (Revenue, USD Mn, 2021 - 2033)
Chemotherapy
Radiotherapy
Immunotherapy
Others
By End User (Revenue, USD Mn, 2021 - 2033)
Hospitals & Clinics
Diagnostic Centers
Biopharmaceutical Companies
Others
By Region (Revenue, USD Mn, 2021 - 2033)
North America
- U.S.
- Canada
Latin America
- Brazil
- Argentina
- Mexico
- Rest of Latin America
Europe
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
Middle East
- GCC Countries
- Israel
- Rest of Middle East
Africa
- South Africa
- North Africa
- Central Africa
Top companies in Global Artificial Intelligence in Oncology Market
Azra AI
IBm Corporation
Siemens Healthineers AG
Intel Corporation
GE HealthCare
NVIDIA Corporation
Digital Diagnostics Inc.
ConcertAI
Median Technologies
PathAI
Microsoft
Zebra Medical Vision
Babylon

1. Research Objectives and Assumptions

Research Objectives
Assumptions
Abbreviations

2. Market Purview

Report Description
- Market Definition and Scope
Executive Summary
- Top 3 Market Findings
- Top 3 Market Opportunity

3. Key Industry Insights

Market Dynamics
Drivers
Restraints
Opportunities
Impact Analysis
Pest Analysis
Porters Analysis
Technological Advancement
Merger, Acquisition and Collaboration Scenario
Recent Product Approvals/Launches
Company Market Share Analysis

4. Artificial Intelligence In Oncology Market, By Component Type, 2021 - 2033 (USD Mn)

Introduction
- Market Size and Forecast, 2021 - 2033, ( USD Mn)
- Segment Trends
Software Solutions, 2021 - 2033( USD Mn)
- Introduction
- Market Size and Forecast, 2021 - 2033, ( USD Mn)
Hardware, 2021 - 2033( USD Mn)
- Introduction
- Market Size and Forecast, 2021 - 2033, ( USD Mn)
Services, 2021 - 2033( USD Mn)
- Introduction
- Market Size and Forecast, 2021 - 2033, ( USD Mn)

5. Artificial Intelligence In Oncology Market, By Cancer Type, 2021 - 2033 (USD Mn)

Introduction
- Market Size and Forecast, 2021 - 2033, ( USD Mn)
- Segment Trends
Breast Cancer, 2021 - 2033( USD Mn)
- Introduction
- Market Size and Forecast, 2021 - 2033, ( USD Mn)
Lung Cancer, 2021 - 2033( USD Mn)
- Introduction
- Market Size and Forecast, 2021 - 2033, ( USD Mn)
Prostate Cancer, 2021 - 2033( USD Mn)
- Introduction
- Market Size and Forecast, 2021 - 2033, ( USD Mn)
Colorectal Cancer, 2021 - 2033( USD Mn)
- Introduction
- Market Size and Forecast, 2021 - 2033, ( USD Mn)
Brain Tumor, 2021 - 2033( USD Mn)
- Introduction
- Market Size and Forecast, 2021 - 2033, ( USD Mn)
Others, 2021 - 2033( USD Mn)
- Introduction
- Market Size and Forecast, 2021 - 2033, ( USD Mn)

6. Artificial Intelligence In Oncology Market, By Treatment Type, 2021 - 2033 (USD Mn)

Introduction
- Market Size and Forecast, 2021 - 2033, ( USD Mn)
- Segment Trends
Chemotherapy, 2021 - 2033( USD Mn)
- Introduction
- Market Size and Forecast, 2021 - 2033, ( USD Mn)
Radiotherapy, 2021 - 2033( USD Mn)
- Introduction
- Market Size and Forecast, 2021 - 2033, ( USD Mn)
Immunotherapy, 2021 - 2033( USD Mn)
- Introduction
- Market Size and Forecast, 2021 - 2033, ( USD Mn)
Others, 2021 - 2033( USD Mn)
- Introduction
- Market Size and Forecast, 2021 - 2033, ( USD Mn)

7. Artificial Intelligence In Oncology Market, By Region, 2021 - 2033, (USD Mn)

Introduction
- Market Share Analysis, 2021 - 2033, ( USD Mn)
- Segment Trends
North America
- Introduction
- Market Size and Forecast, By Component Type, 2021 - 2033, ( USD Mn)
- Market Size and Forecast, By Cancer Type, 2021 - 2033, ( USD Mn)
- Market Size and Forecast, By Treatment Type, 2021 - 2033, ( USD Mn)
- Market Size and Forecast, By Country, 2021 - 2033, ( USD Mn)
  - U.S.
  - Canada
Europe
- Introduction
- Market Size and Forecast, By Component Type, 2021 - 2033, ( USD Mn)
- Market Size and Forecast, By Cancer Type, 2021 - 2033, ( USD Mn)
- Market Size and Forecast, By Treatment Type, 2021 - 2033, ( USD Mn)
- Market Size and Forecast, By Country, 2021 - 2033, ( USD Mn)
  - U.K
  - Germany
  - France
  - Italy
  - Spain
  - Russia
  - Rest of Europe
Asia Pacific
- Introduction
- Market Size and Forecast, By Component Type, 2021 - 2033, ( USD Mn)
- Market Size and Forecast, By Cancer Type, 2021 - 2033, ( USD Mn)
- Market Size and Forecast, By Treatment Type, 2021 - 2033, ( USD Mn)
- Market Size and Forecast, By Country, 2021 - 2033, ( USD Mn)
  - China
  - India
  - Japan
  - Australia
  - South Korea
  - ASEAN
  - Rest of Asia Pacific
Latin America
- Introduction
- Market Size and Forecast, By Component Type, 2021 - 2033, ( USD Mn)
- Market Size and Forecast, By Cancer Type, 2021 - 2033, ( USD Mn)
- Market Size and Forecast, By Treatment Type, 2021 - 2033, ( USD Mn)
- Market Size and Forecast, By Country, 2021 - 2033, ( USD Mn)
  - Brazil
  - Mexico
  - Argentina
  - Rest of Latin America
Middle East
- Introduction
- Market Size and Forecast, By Component Type, 2021 - 2033, ( USD Mn)
- Market Size and Forecast, By Cancer Type, 2021 - 2033, ( USD Mn)
- Market Size and Forecast, By Treatment Type, 2021 - 2033, ( USD Mn)
- Market Size and Forecast, By Country, 2021 - 2033, ( USD Mn)
  - GCC
  - Israel
  - Rest of Middle East
Africa
- Introduction
- Market Size and Forecast, By Component Type, 2021 - 2033, ( USD Mn)
- Market Size and Forecast, By Cancer Type, 2021 - 2033, ( USD Mn)
- Market Size and Forecast, By Treatment Type, 2021 - 2033, ( USD Mn)
- Market Size and Forecast, By Country, 2021 - 2033, ( USD Mn)
  - North Africa
  - Central Africa
  - South Africa